Related Experiment Video
Updated: Jan 13, 2026
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
16.2K
Population-Based Outcomes of Single-Fraction Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung
J M Callueng1, S Baker2, N Chng3
1Division of Radiation Oncology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; Department of Radiation Oncology, BC Cancer Kelowna, Kelowna, British Columbia, Canada.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 9, 2026
Summary
Single-fraction stereotactic ablative radiotherapy (SF-SABR) offers favorable outcomes for early-stage non-small cell lung cancer (NSCLC). This treatment shows comparable results and low toxicity, making it a viable option for patients.
Area of Science:
- Oncology
- Radiation Oncology
- Thoracic Surgery
Background:
- Single-fraction stereotactic ablative radiotherapy (SF-SABR) emerged during the COVID-19 pandemic in British Columbia (BC).
- It is now a standard treatment due to comparable outcomes with fractionated regimens and benefits in resource use and patient convenience.
- This study assesses SF-SABR for early-stage non-small cell lung cancer (NSCLC) in BC.
Purpose of the Study:
- To evaluate the clinical outcomes of SF-SABR in patients with early-stage NSCLC.
- To assess the toxicity profiles associated with SF-SABR treatment.
- To compare SF-SABR outcomes with existing data from fractionated regimens and other SABR studies.
Main Methods:
- A multi-institution, population-based retrospective study of patients treated with SF-SABR for early-stage NSCLC between March 2020 and August 2023 in BC.
- Inclusion criteria: peripheral T1-T2 tumors (<5 cm), medically inoperable or surgical declination.
- Prescription doses: 30 Gy or 34 Gy in one fraction; outcomes assessed: 2-year local failure (LF), distant failure (DF), overall survival (OS), and toxicity (CTCAE v5.0).
Main Results:
- 179 lesions in 166 patients were analyzed with a median follow-up of 23.0 months.
- 2-year LF, DF, and OS rates were 7.1%, 14.1%, and 81.5%, respectively.
- No grade 4/5 toxicities; grade 2/3 toxicities at 17.3%/2.2%. Chest wall toxicity (CWT) rates were 5.6% (grade 2) and 0.6% (grade 3).
Conclusions:
- SF-SABR demonstrates favorable early clinical outcomes and low toxicity for early-stage NSCLC.
- Results are comparable to other SF-SABR and multi-fraction lung SABR studies.
- Long-term follow-up is necessary to further evaluate outcomes and toxicity of SF-SABR.
